No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.4x · 10Y median 2.3x · 20th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:56.894Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for bioAffinity Technologies, Inc. (BIAF) stock was $6.19 as of Oct 5, 2026, 4:00 PM EDT, up 2.23% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -84.0% · 3-year avg -78.3%/yr
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer.
Medical - Diagnostics & Research · San Antonio, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 18, 2026
43 days away
EPS Estimate
-31.50
Revenue Est.
$1.91M
Last Quarter Results
EPS
$-71.10
vs Estimate
$-40.50
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BIAF | $2.59M | $6.19 | +2.23% | -84.05% | N/A | N/A | N/A |
| 2ISPC | $2.64M | $1.05 | -2.78% | -97.66% | -81.14% | N/A | vs BIAF |
| 3FBLG | $2.47M | $1.18 | -4.84% | -89.14% | N/A | N/A | vs BIAF |
| 4ITOC | $2.38M | $0.25 | +1.85% | N/A | N/A | N/A | vs BIAF |
| 5CELZ | $2.37M | $0.92 | -2.79% | -71.43% | -57.96% | -72.19% | vs BIAF |
| 6GOVX | $2.36M | $0.32 | -0.06% | N/A | N/A | N/A | vs BIAF |
forward FY estimate
N/A
$1.51M
vs Estimate
$1.70M
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$6.19
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-31.50 | $-31.50 | $-31.50 | 1 |
| Quarter ending Dec 2026 | $-27.00 | $-27.00 | $-27.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-121.50 | $-121.50 | $-121.50 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.91M | $1.91M | $1.91M | 1 |
| Quarter ending Dec 2026 | $2.22M | $2.22M | $2.22M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $7.31M | $7.31M | $7.31M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
